PolyPid regains European rights for D-PLEX after deal ends

PolyPid Ltd., an Israeli biopharmaceutical company, has regained exclusive European commercialization rights for its long-acting, controlled-release drug D-PLEX₁₀₀ after mutually agreeing to terminate a 2022 partnership with ADVANZ PHARMA. The press release from PolyPid states that the termination of the exclusive License, Distribution, and Supply Agreement returns those rights to the company.

CEO Dikla Czaczkes Akselbrad expressed gratitude for the collaboration with ADVANZ PHARMA over the past years but declined to disclose financial terms or the reason behind the termination. Since the 2022 agreement, PolyPid has successfully completed its Phase 3 SHIELD II trial, submitted a New Drug Application to the U.S. Food and Drug Administration, and established a North American commercialization partnership with Azurity Pharmaceuticals.

D-PLEX₁₀₀ is designed to prevent surgical site infections and met its primary and all key secondary endpoints in the trial. PolyPid specializes in developing drugs for surgical care, metabolic diseases, and other medical needs.